Tislelizumab - Beigene

Drug Profile

Tislelizumab - Beigene

Alternative Names: BGB A317

Latest Information Update: 14 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator BeiGene
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Fc receptor modulators; PDCD 1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Lung cancer
  • Phase II Gastric cancer; Hodgkin's disease; Oesophageal cancer; Urogenital cancer
  • Phase I B cell lymphoma; Solid tumours

Most Recent Events

  • 11 Dec 2017 Initial efficacy and adverse events data from a phase Ib trial in B-cell lymphoma presented at the 59th Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem 2017)
  • 13 Nov 2017 Phase-III clinical trials in Lung cancer (Late-stage disease, Second-line therapy or greater) in China (Parenteral)
  • 13 Nov 2017 BeiGene completes enrolment in its phase Ia/Ib trial for Solid tumours (Late-stage disease, Monotherapy) in New Zealand, Australia, South Korea, Taiwan and USA (NCT02407990)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top